
DATE: March 11, 2019

TO: PREP-AP CLINICAL NETWORK PROVIDERS AND PREP-AP ENROLLMENT WORKERS

SUBJECT: ADDITION OF HEPATITIS B RECOMBINANT VACCINE TO THE PREP-AP FORMULARY

Effective January 30, 2019, Heplisav-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), a two-dose hepatitis B virus vaccine, has been added to the PrEP-AP formulary. Heplisav-B received federal Food and Drug Administration approval on November 9, 2017 for the prevention of infection by all known subtypes of hepatitis B. The ADAP Medical Advisory Committee voted to recommend the addition of this vaccine to the PrEP-AP formulary on December 19, 2018.

The Heplisav-B vaccine will also be available to PrEP-AP clients for administration in a clinical setting. PrEP-AP Policy Provider Memo 2018-01: Physician-Administered Medication has been updated to reflect the addition of the vaccine and provides instruction for providers to bill PrEP-AP for administration.

ADAP management requests that you the share this information with your clinical leadership team and local prescribers. The PrEP-AP formulary has been updated to reflect the addition of this vaccine; it can be access at the following link: https://cdphprep-ap.magellanrx.com/member/documents.

If you have any questions regarding the addition of this vaccine to the PrEP-AP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

Adrian Barraza, Chief
ADAP Program, Policy, and Fiscal Section
California Department of Public Health